These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 31919231)
1. S100A11/ANXA2 belongs to a tumour suppressor/oncogene network deregulated early with steatosis and involved in inflammation and hepatocellular carcinoma development. Sobolewski C; Abegg D; Berthou F; Dolicka D; Calo N; Sempoux C; Fournier M; Maeder C; Ay AS; Clavien PA; Humar B; Dufour JF; Adibekian A; Foti M Gut; 2020 Oct; 69(10):1841-1854. PubMed ID: 31919231 [TBL] [Abstract][Full Text] [Related]
2. Tristetraprolin Promotes Hepatic Inflammation and Tumor Initiation but Restrains Cancer Progression to Malignancy. Dolicka D; Sobolewski C; Gjorgjieva M; Correia de Sousa M; Berthou F; De Vito C; Colin DJ; Bejuy O; Fournier M; Maeder C; Blackshear PJ; Rubbia-Brandt L; Foti M Cell Mol Gastroenterol Hepatol; 2021; 11(2):597-621. PubMed ID: 32987153 [TBL] [Abstract][Full Text] [Related]
3. The S100 calcium-binding protein A11 promotes hepatic steatosis through RAGE-mediated AKT-mTOR signaling. Teng F; Jiang J; Zhang J; Yuan Y; Li K; Zhou B; Zhou X; Liu W; Zhang P; Liu D; Zheng M; Lu Y; Zhang H Metabolism; 2021 Apr; 117():154725. PubMed ID: 33571540 [TBL] [Abstract][Full Text] [Related]
5. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model. Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720 [TBL] [Abstract][Full Text] [Related]
7. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Moeini A; Torrecilla S; Tovar V; Montironi C; Andreu-Oller C; Peix J; Higuera M; Pfister D; Ramadori P; Pinyol R; Solé M; Heikenwälder M; Friedman SL; Sia D; Llovet JM Gastroenterology; 2019 Nov; 157(5):1383-1397.e11. PubMed ID: 31344396 [TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet. Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242 [TBL] [Abstract][Full Text] [Related]
9. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328 [TBL] [Abstract][Full Text] [Related]
10. NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. Ma C; Kesarwala AH; Eggert T; Medina-Echeverz J; Kleiner DE; Jin P; Stroncek DF; Terabe M; Kapoor V; ElGindi M; Han M; Thornton AM; Zhang H; Egger M; Luo J; Felsher DW; McVicar DW; Weber A; Heikenwalder M; Greten TF Nature; 2016 Mar; 531(7593):253-7. PubMed ID: 26934227 [TBL] [Abstract][Full Text] [Related]
11. Absence of Either Ripk3 or Mlkl Reduces Incidence of Hepatocellular Carcinoma Independent of Liver Fibrosis. Mohammed S; Thadathil N; Ohene-Marfo P; Tran AL; Van Der Veldt M; Georgescu C; Oh S; Nicklas EH; Wang D; Haritha NH; Luo W; Janknecht R; Miller BF; Wren JD; Freeman WM; Deepa SS Mol Cancer Res; 2023 Sep; 21(9):933-946. PubMed ID: 37204757 [TBL] [Abstract][Full Text] [Related]
12. Hepatocellular proliferation correlates with inflammatory cell and cytokine changes in a murine model of nonalchoholic fatty liver disease. Vansaun MN; Mendonsa AM; Lee Gorden D PLoS One; 2013; 8(9):e73054. PubMed ID: 24039859 [TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. Frau M; Feo F; Pascale RM J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184 [TBL] [Abstract][Full Text] [Related]
14. S100 Proteins in Fatty Liver Disease and Hepatocellular Carcinoma. Delangre E; Oppliger E; Berkcan S; Gjorgjieva M; Correia de Sousa M; Foti M Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232334 [TBL] [Abstract][Full Text] [Related]
15. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349 [TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma. Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237 [TBL] [Abstract][Full Text] [Related]
18. Involvement of S100A6/S100A11 in T-Cell Immune Regulatory in HCC Revealed by Single Cell RNA-seq. Zhou R; Pei B; Li X; Zhang X Technol Cancer Res Treat; 2024; 23():15330338241252610. PubMed ID: 38766816 [No Abstract] [Full Text] [Related]
19. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]